SAN DIEGO, Oct. 6 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Stephen M. Coutts, Ph.D. as CEO, President and Director and the appointment of Edward A. Dennis, Ph.D., as Director. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. Janko.
"We are pleased to welcome Dr. Coutts, a highly regarded professional in our field, and believe he is a good fit with our development strategy," said Claire K.T. Reiss, Chairman of the Board. "In addition, we are honored to add Dr. Dennis to the Board and look forward to benefiting from his extensive experience and perspective. On behalf of the Biocept Board of Directors, I would also like to thank Mr. Janko for his contributions during the five years that he led Biocept," Ms. Reiss added.
"I am delighted to join Biocept at this critical time and look forward to continuing to develop and grow this exciting technology," said Dr. Coutts.
Dr. Coutts has 30 years of experience in the pharmaceutical and biotechnical industries. He was most recently Director of Pharmaceutical Development at Cypress Bioscience, Inc. and a principal at Alembic Biotech Consultants. He was previously President and COO at Triad Therapeutics, Inc. and spent 11 years as Executive Vice President for R&D at La Jolla Pharmaceutical. Dr. Coutts holds a BS in Chemistry from San Diego State University, a Ph.D. in Biochemistry from Harvard University and an MBA from New York University.
Dr. Dennis is Distinguished Professor of Chemistry and Biochemistry and
of Pharmacology in the School of Medicine at the University of California
at San Diego (UCSD). He is currently Editor-in-Chief of the Journal of
Lipid Research and has been named a Fellow of the American Association for
the Advancement of Sciences. Dr. Dennis serves on the Scientific Advisory
Board and Board of Directors of several private and public companies. He
|SOURCE Biocept, Inc.|
Copyright©2008 PR Newswire.
All rights reserved